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Strong evidence showed neurotoxic properties of beta amyloid (Aβ) and its pivotal
role in the Alzheimer’s disease (AD) pathogenesis. Beside, experimental data suggest
that Aβ may have physiological roles considering that such soluble peptide is
produced and secreted during normal cellular activity. There is now suggestive
evidence that neurodegenerative conditions, like AD, involve nitric oxide (NO) in
their pathogenesis. Nitric oxide also possess potent neuromodulatory actions in
brain regions, such as prefrontal cortex (PFC), hippocampus (HIPP), and nucleus
accumbens (NAC). In the present study, we evaluated the effect of acute Aβ injection
on norepinephrine (NE) content before and after pharmacological manipulations of
nitrergic system in above mentioned areas. Moreover, effects of the peptide on NOS
activity were evaluated. Our data showed that 2 h after i.c.v. soluble Aβ administration,
NE concentrations were significantly increased in the considered areas along with
increased iNOS activity. Pre-treatment with NOS inhibitors, 7-Nitroindazole (7-NI),
and N6-(1-iminoethyl)-L-lysine-dihydrochloride (L-NIL), reversed Aβ-induced changes.
Ultimately, pharmacological block of interleukin1 (IL-1) receptors prevented NE increase
in all brain regions. Taken together our findings suggest that NO and IL-1 are critically
involved in regional noradrenergic alterations induced by soluble Aβ injection.
Keywords: soluble beta amyloid, norepinephrine, nitric oxide, interleukin-1, prefrontal cortex, hippocampus,
nucleus accumbens
Abbreviations:AD,Alzheimer’s disease; Aβ, soluble beta amyloid; 7-NI, 7-Nitroindazole; L-NIL, N6-(1-iminoethyl)-L-lysine-
dihydrochloride; PFC, prefrontal cortex; HIPP, hippcampus; NAC, nucleus accumbens; NO, nitric oxide; iNOS, inducible
Nitric oxide synthase; eNOS, endotelial Nitric oxide synthase; nNOS, neuronal Nitric oxide synthase; NOx, nitrates and
nitrites; NE, norepinephrine; IL-1, interleukin 1; IL-1ra, interleukin 1 receptor antagonist.
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INTRODUCTION
Amyloid beta peptide (Aβ) is the main component of the amyloid
plaques, one of the neuropathological hallmarks of Alzheimer’s
disease (AD; Di Carlo et al., 2012). It has been hypothesized
that the peptide accumulation initiated by a pathogenic cascade
ultimately leads to AD (Hardy and Selkoe, 2002). However,
mounting evidence suggest that Aβ, besides its well accepted
neurotoxic activity, may have physiological roles (Mura et al.,
2010a). The peptide, in its soluble form, is produced and secreted
during normal cellular activity (Kar et al., 2004) and is able
to modulate synaptic activity in the absence of neurotoxicity
(Grilli et al., 2010; Mura et al., 2010b). Physiologically, the
neuromodulatory role of Aβ would be important for the
right functioning of neurotransmitter systems; however, in
pathological conditions, Aβ-modulating synaptic activity could
trigger functional alterations on neurotransmission (Mura et al.,
2012).
On the other hand, several hints point to the involvement
of the free radical gas, nitric oxide (NO), in the pathogenesis
of neurodegenerative conditions, such as AD (Guix et al., 2005;
Fernandez et al., 2010). In the brain, NO is synthesized from L-
Arginine (L-Arg) either by inducible nitric oxide synthase (iNOS)
in microglia and astrocytes, or by constitutive NOS in neurons
and endothelial cells (nNOS and eNOS, respectively). It has been
suggested that NO produced by constitutive NOS is accountable
for neuroprotection from Aβ-induced cell death, while NO
release, following iNOS activation, plays a neurotoxic role (Puzzo
et al., 2006). The three NOS isoforms have been proposed to
mediate Aβ effects, producing elevated levels of NO, which could
contribute to worsen the outcomes of the disease (Fernandez
et al., 2010). Although NO behaves as a neurotoxic effector when
produced in excessive amount, increasing evidence focus on its
neuroprotective properties in mediating cellular transduction
mechanisms, regulating neuronal plasticity (Palumbo et al., 2007)
and suppressing neuronal apoptotic cell death (Contestabile and
Ciani, 2004). By playing a potent neuromodulatory role in several
brain regions, such as prefrontal cortex (PFC), hippocampus
(HIPP), nucleus accumbens (NAC), and striatum (Trabace et al.,
2004, 2007; Saulskaya et al., 2010; Bechade et al., 2011), NO
has been presented either as neuroprotective or restorative in
neurodegenerative conditions such as AD (Puzzo et al., 2005).
Recent evidence linked Aβ effects to the nitrergic pathway;
indeed, as suggested by experiments performed in mouse and
human cells, Aβ caused a decrease in the activity of the soluble
guanylate cyclase sinking NO signaling by binding to the cell
surface receptor CD36 (Miller et al., 2010). Therefore, the
enhancement of NO levels can be proposed as protective toward
neurons from their degeneration and death.
Interestingly, there is several in vivo and in vitro evidence
supporting the NO pathway’s role in the mechanism of
norepinephrine (NE)-induced neuroprotection (Lonart et al.,
1992; Chen et al., 2006; Chen and Russo-Neustadt, 2007).
Indeed, in primary hippocampal neuronal cell culture, NE
stimulation leads to an increased activation of several pathways,
whose function has been proposed to be dependent on NO
availability. Furthermore, such activation seems to be decreased
in presence of NOS inhibition (Chen and Russo-Neustadt, 2007).
In addition, it has been shown that NE promotes cell survival
both in vivo (Chen and Russo-Neustadt, 2005) and in the primary
hippocampal neuronal cell culture (Chen and Russo-Neustadt,
2007). Previous reports also indicate that NE is an important
player in innate immunosuppressive maintenance within the
central nervous system (Feinstein et al., 2002; Heneka et al.,
2002); it has been reported that NE holds anti-inflammatory
properties by modulating microglial functions following the
degeneration of aminergic locus coeruleus (LC) neurons induced
in APP-transgenic mice by using the neurotoxin DSP4 (Heneka
et al., 2010). In particular, it has been shown that NE, through
the activation of β2 adrenoceptors present on microglial cells, is
able to promote endocytosis and degradation of Aβ42 (Kong et al.,
2010). Furthermore, NE can significantly reduce glial iNOS via
activation of β2 adrenoceptors and cAMP increase (Kalinin et al.,
2006).
Based on the above reported background, we were firstly
interested in evaluating the interplay among Aβ peptide,
noradrenergic, and nitrergic transmission. To this end,
we evaluated effects of an acute soluble Aβ injection on
noradrenergic neurotransmission; moreover, by using NOS
inhibitors, we tested if such pharmacological manipulations of
the nitrergic system were able to modulate the neurochemical
effects induced by Aβ peptide in brain areas involved in AD, such
as PFC, HIPP, and NAC.
In addition, we have previously demonstrated that
intrahippocampal injection of soluble Aβ potently increases
interleukin-1β levels (Sanz et al., 2009). Such cytokine has been
reported to act at distance with NO mediating central NE effect
(Hsieh et al., 2010). Thus, we further investigated the effect of




A total of 78 young adult male (250–300 g) Wistar rats (Harlan,
S. Pietro al Natisone, Udine) were used in this study. They
were housed at constant room temperature (22 ± 1◦C) and
relative humidity (55 ± 5%) under a 12 h light/dark cycle
with ad libitum access to standard food and water. Procedures
involving animals and their care were conducted in conformity
with the institutional guidelines of the Italian Ministry of Health
(D.L. 26/2014), the Guide for the Care and Use of Mammals
in Neuroscience and Behavioral Research (National Research
Council, 2004), the Directive 2010/63/EU of the European
Parliament and of the Council of 22 September 2010 on the
protection of animals used for scientific purposes. All procedures
involving animals were conducted in accordance to ARRIVE
guidelines. Animal welfare was daily monitored through the
entire period of experimental procedures. No signs of distress
were evidenced; anyway, all efforts were made to minimize the
number of animals used and their suffering.
Cannula Implantation and Aβ
Administration
Cannula implantation was performed as previously described
(Trabace et al., 2007). Briefly, unilateral 23-gauge stainless
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steel guide cannulae (Cooper’s Needles, Birmingham, UK) were
implanted using the following coordinates relative to bregma:
AP = −0.5, L = +1.2, H = −3.0 with the incisor bar set
at −3.3mm, according to a stereotaxic atlas (Paxinos and
Watson, 1998). On the day of the experiment, Aβ(1-42) fresh
solution, at a concentration previously tested (4µM, in distilled
water; Colaianna et al., 2010), was delivered via a 30-gauge
needle lowered 2mm below the cannula tip. The solution was
then infused at a flow rate of 2µL/min for 2min 30 s through
a Hamilton syringe connected to a microdialysis pump (CMA
microdialysis, Sweden).
Atomic Force Microscopy (AFM) and
Transmission Electron Microscopy (TEM)
Samples for AFM and TEM measurements were obtained by
preparing a 4µM solution of Aβ, both for the “initial state”
and the “oligomers” phase. Freshly prepared 4µM solution of
Aβ was used immediately (“initial state solution”). To obtain
Aβ oligomers, a different 4µM solution of Aβ was prepared
in 50mM phosphate buffer and 150mM NaCl (pH 7.4), and
incubated for 24 h at 4◦C (“oligomers” solution; Lambert et al.,
1998).
For AFM analyses, some drops of the solution were deposited
on a freshly cleaved mica substrate. After an incubation of 2min,
samples were washed with ultrapure water and dried for 30min
in a vacuum desiccator.
A Perception Atomic Force Microscope (Assing S.p.A., Italy)
was used to record AFM images. Measurements were performed
in air, working in the weak repulsive regime of contact mode.
Gold coated Si3N4 cantilevers (model MSNL from Bruker
Company, Massachusetts, USA) with a spring constant of 0.01
N/m and Silicon tips with a nominal apical radius of 2–12 nm
were used for the topographic AFM images. Constant force
images were acquired with a scan rate of about 8 s/row, at a
resolution of 512× 512 points.
For TEM analyses, a little drop (20µL) of each incubated
sample solution was applied to carbon coated copper/rhodium
grid (400 mesh; TAAB Laboratories Equipment Ltd,
Aldermaston, Berks, GB). The coated grid was floated for
2min on the sample drop and rinsed with 200mL of double
distilled water. Negative staining was performed with 200µL of
2% w/v uranyl acetate solution (TAAB Laboratories Equipment
Ltd). After draining off the excess of staining solution by means
of a filter paper, the specimen was transferred for examination
in a Philips Morgagni 282D transmission electron microscope,
operating at 60 kV. Electron micrographs of negatively stained
samples were photographed on Kodak electron microscope film
4489 (Kodak Company, New York, USA).
Pharmacological Manipulation
Thirty minute before Aβ administration, NOS inhibitors 7-
Nitroindazole (7-NI) (50mg kg−1, Vinci Biochem, Florence,
Italy), and N6-(1-iminoethyl)-L-lysine-dihydrochloride (L-NIL)
(5mg kg−1, Vinci Biochem, Florence, Italy) were dissolved in
saline (1ml kg−1, veh) and administered intraperitoneally (i.p.)
(Trabace et al., 2007) according to the experimental assignment.
Interleukin-1 receptor antagonist (IL-1ra, Sigma-Aldrich, Milan,
Italy) was applied i.c.v. at a concentration of 100 ng 5µl−1 per
rat (Taepavarapruk and Song, 2010). Drugs were administered
30min (NOS inhibitors) or 10min (IL-1ra) before Aβ injection
based upon our previous experience and following a survey of
the relevant literature (Trabace et al., 2007; Choi et al., 2009).
Post-mortem Tissue Analysis
Rats were euthanized and brains were immediately removed 2 h
after Aβ administration. Thereafter, PFC, NAC, and HIPP were
collected and stored frozen at−80◦Cuntil analyses. Samples were
treated and NE and serotonin (5-HT) tissue concentrations were
determined by using high performance liquid chromatography
(HPLC) coupled with electrochemical detection as previously
described (Trabace et al., 2011).
HPLC Analysis
NE and 5-HT concentrations were determined by HPLC coupled
with an electrochemical detector (INTRO, Antec Leyden, The
Netherlands). Separation was performed by a LC18 reverse phase
column (hypersil, 150 × 3mm, ODS 5µm; Thermoscientific,
Milan, Italy). The detection was accomplished by a Unijet cell
(BASi, Kenilworth, U.K.) with a 6mm diameter glassy carbon
electrode at a working potential of 0.65V vs. Ag/AgCl. The
mobile phase used was 85mM CH3COONa, 0.8mM octane
sulfonic acid, 0.3mM EDTA, 15mM NaCl, methanol 6%, in
distilled water, buffered at pH 4.85. The flow rate was maintained
by an isocratic pump (Shimadzu LC-10 AD, Kyoto, Japan) at
1ml/min. Data were acquired and integrated using Chromeleon
software (version 6.60, Dionex, San Donato Milanese, Italy).
Quantification of NOS Gene Expression
RNA Extraction
Total RNA was extracted from PFC, NAC, and HIPP by using
Nucleospin RNA II kits (Macherey-Nagel, Dublin, Ireland)
according to the manufacturer’s instructions. Total RNA
concentrations were measured with a NanoDrop R© (Thermo
Scientific, Dublin, Ireland) micro-volume spectrophotometer
and all RNA samples were equalized with RNase-free water to the
lowest detected concentration.
cDNA Synthesis
cDNA was synthesized using the ABI High Capacity cDNA
kit (Applied Biosystems, life technologies, Paisley, U.K.) as
provided by the protocol. A 2X master-mix solution containing
reverse transcription buffer, dNTPs, random primers, and
MultiScribeTM reverse transcriptase was made up in RNase-
free water and stored on ice. The reverse transcription reaction
was performed in a thermocycler (PTC-200, MJ Research) with
a three-step program: 10min at 25◦C followed by 120min at
37◦C and a final 5min step at 85◦C. cDNA samples were used
immediately for real time PCR or stored at−20◦C until needed.
Real-time PCR
Real-Time PCR was performed as multiplex using TaqMan R©
Gene Expression Assays in accordance with the manufacturer’s
instructions (Applied Biosystems, life technologies, Paisley,
U.K.). The target genes nNOS (Rn00583793), iNOS
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(Rn00561646), and eNOS (Rn02132634) were identified by
FAM-labeled probes, while the housekeeping gene of reference,
β–actin (4352340E), was identified by a VIC-labeled probe. The
mixture was prepared by adding a 1:5 dilution of the cDNA
sample obtained from the previous reaction into a 96-well optical
reaction plate (Applied Biosystems, life technologies, Paisley,
U.K.), followed by 2X TaqMan R© Universal PCR Master Mix
(No AmpErase R© UNG, Applied Biosystems, life technologies,
Paisley, U.K.) and 20X primers for both the target gene and
β-actin (to reach a final 1X concentration). Amplification
reaction was achieved with a three-stage protocol: 2min at 50◦C
followed by 10min at 95◦C, followed again by 40 repetitions
of a two-step cycle composed by 15 s at 95◦C (denaturation)
and 1min at 60◦C (annealing and extension) (ABI Prism 7300
instrument, Applied Biosystems, life technologies, Paisley, U.K.).
Data analysis was performed with the 7300 System Software
(Applied Biosystems, life technologies, Paisley, U.K.) and RQ
values (2-11CT, where CT is the threshold cycle) of the target
genes relative to their own endogenous control were obtained.
The RQ values were then converted into fold change values
relative to control group. β-actin was used as the reference
housekeeping gene in this study.
Nitrite/Nitrate (NOx) Analysis
NOx levels were estimated using an ion chromatographic
with conductometric detection method. The brain areas were
suspended (1:20, w/v) in ultrapure water and placed at 70◦C for
5min. After cooling, the mixture was centrifuged for 5min at
1500× g at room temperature. Chromatographic determinations
were performed on a Dionex DX-500 system (Dionex
Corporation, Sunnyvale, CA, USA) injecting 25µL of the
supernatant. Chromatographic separations were accomplished
using an IonPac AS9-HC column (250 × 4mm) associated with
a pre-column AG9-HC (4mm, Dionex Corporation) eluted in
isocratic mode at a flow rate of 1.0mL/min. The mobile phase
consisted of 9mM sodium carbonate (total run time, 20min)
(Iammarino et al., 2012).
Statistical Analysis
Results were expressed as percentage of control (SHAM-veh) and
mean ± S.E.M. Statistical analyses were performed using Graph
Pad 5.0 (GraphPad Software, San Diego, CA) and Systat13 (Systat
Software, Inc. San Jose, CA) for Windows. Neurotransmitter
concentrations were analyzed using Two-way analysis of variance
(ANOVA) followed by Bonferroni multiple comparisons test.
NOx concentrations and NOS mRNA content were analyzed
by using Student’s t-test for independent comparison and Two-
way ANOVA followed by Bonferroni multiple comparisons test,
as required. Differences were considered statistically significant
when P-value was less than 0.05.
RESULTS
Evaluation of Aβ State through AFM and
TEM Measurements
Figure 1 shows AFM images of “initial state” and “oligomers”
solution of Aβ deposited on a freshly cleaved mica disk. It is
evident that in both cases Aβ particles with different sizes are
distributed on the mica substrate. The size of such particles was
estimated by sphericity assumption, considering height values,
because the lateral size is influenced by tip-particle convolution.
In fact, Figure 1A showed that the “initial state” solution
contained many small particles and very few larger particles. As
indicated in Figure 1B, the distribution of height values of the
small particles (height less than about 2.5 nm), peaked in the 0.9–
1.2 nm range with amean value of 1.2± 0.5 nm. The height of the
few larger particles (height more than about 2.5 nm) was more
uniformly distributed and was characterized by a mean value of
3.9 ± 0.6 nm. After 24 h incubation at 4◦C and pH 7.4, particles
assembled in larger aggregates, as shown in the AFM image of
“oligomers” solution (Figure 1C). In this case, the aggregate sizes
were characterized by a bimodal distribution (Figure 1D), where
the two modal values were related to aggregates with a height
size value smaller or larger than 9 nm, respectively. The smaller
aggregates presented a mean height size of 4.4± 1.7 nm, whereas
the mean height size of larger aggregates was 22.7 ± 6.7 nm.
TEM analyses confirmed results obtained from AFM; indeed,
as shown in Figure 1E, in the “initial state solution” the higher
percentage of molecules were monomers, while in the “oligomer
state solution” oligomers and fibrils were the most representative
species (Figure 1F).
Effects of Nitrergic Manipulation on
Regional NE and 5-HT Concentrations in
Aβ-injected Rats
As shown in Figure 2, NE concentrations were higher in Aβ-
treated when compared to SHAM rats in all of the three areas
investigated (Two-way ANOVA with Bonferroni correction,
PFC:P = 0.038; HIPP P = 0.044; and NAC P = 0.023). The
administration of NOS inhibitors, L-NIL, and 7-NI, 30min prior
to administration of the soluble peptide, prevented this effect
in all brain areas (Figure 2, Two-way ANOVA with Bonferroni
correction, n.s.). No differences were found between Aβ-treated
and SHAM rats in 5-HT content in all three areas investigated
(data not shown), thus no pharmacological manipulation of
nitrergic system was further carried out.
Effects of Aβ Administration and
Pharmacological Manipulation on NOS
Expression
To investigate if Aβ administration was able to affect NOS
expression, mRNA content of NOS enzymes (neuronal,
endothelial, and inducible forms) was evaluated. A significant
increase of iNOS was detected in the PFC (Student’s t-test,
P = 0.028), NAC (Student t-test, P = 0.041) and HIPP
(Student’s t-test, P = 0.031) of Aβ-treated rats, while nNOS was
not affected in these brain areas (Figure 3). Moreover, results
showed that eNOS mRNA was decreased only in HIPP (Student’s
t-test, P = 0.016), while no difference was evident in PFC and
NAC (Figure 3). To evaluate iNOS activity, NOx levels were
measured. Statistical analysis showed that the soluble peptide
induced a strong increase in NOx levels in PFC (Student’s t-test,
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FIGURE 1 | (A) AFM picture measured in contact mode by using Silicon tips having a nominal apical radius of 2–12 nm and (B) histogram representing the distribution
of height size values of Aβ “initial state” solution deposited on a freshly cleaved mica disk. In (C,D) are reported the corresponding AFM picture and distribution of
height size values for an “oligomer” solution of Aβ deposited on a freshly cleaved mica disk. The color scale reported on the right hand side of each AFM picture
represents the height values of the measured structures. In (E,F), TEM pictures of “initial state” and “oligomer state” solutions, respectively, are reported. The
horizontal scale bar was 500 nm for AFM and 50 nm for TEM picture.
P = 0.046), HIPP (Student’s t-test, P = 0.003), and NAC
(Student’s t-test, P = 0.042; Figure 4).
Effects of Block of IL-1β Receptors on
Aβ-induced NE Increase
In order to possibly establish a putative mechanism for the
increase in NE Aβ-induced, we pre-treated the animals with
the antagonist of IL-1 receptors, IL1ra. Results showed that in
all investigated areas such treatment was able to prevent NE
increase in Aβ-treated rats (Figure 5, Two-way ANOVA followed
by Bonferroni post hoc test, n.s.).
DISCUSSION
In the present study, we found that a single i.c.v. injection of
freshly prepared Aβ solution induced a significant increase of
NE concentrations in the PFC, NAC, and HIPP when measured
2 h after administration. Moreover, treatment with nitrergic
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FIGURE 2 | NE levels in PFC, HIPP, and NAC of male Wistar rats 2h
after injection of water (5 µL i.c.v.; SHAM) or Aβ (4 µM, 5 µL i.c.v.; Aβ).
Animals were pre-treated with vehicle (saline, veh, 1ml kg−1), L-NIL (5mg
kg−1, i.p.), or 7-NI (50mg kg−1, i.p.), 30min before i.c.v. administration. Data
are expressed as percentage of control (n = 6–7 per group; Two-way ANOVA
with Bonferroni correction, *P < 0.05).
modulators and with the antagonist of IL-1 receptor prevented
NE increase in Aβ-treated rats. We also found that the increase
was accompanied with an increase in iNOS mRNA levels along
with NOx concentrations in all brain areas investigated.
Although alterations in neurotransmitter secretion have
been extensively reported in the case of other monoaminergic
transmitters (Trabace et al., 2007; Preda et al., 2008; Morgese
et al., 2014), the exact mechanism through which Aβ may alter
NE concentrations in these areas is not completely understood
yet. However, we hypothesized that the altered Aβ-induced NE
content may be caused by messengers/neurotransmitters such
as NO. The free-radical gas NO is produced by NOS and it
modulates vital physiological functions (Moncada et al., 1991;
Murad, 2003) acting as an intercellular messenger, which possess
also neuromodulatory actions (Garthwaite, 1991; Snyder and
Bredt, 1991). Patel and coworkers have demonstrated in vitro
that, at hippocampal level, the activation of the noradrenergic
system is neuroprotective in stressful condition and that, at least
partially, these protective actions are mediated by NO signaling
(Patel et al., 2010). Additionally, NE seems to control both
enzymatic activity and expression of nNOS and iNOS in rat
magnocellular neurons (Grange-Messent et al., 2004). In line
with these observations, in the present study, we demonstrated
that the increase in NE concentrations was accompanied with
higher iNOS mRNA, along with increased NOx concentrations,
suggesting that the effects of Aβ could be associated with
NO-related actions on the noradrenergic system. Indeed, we
have found that pharmacological inhibition of the nitrergic
system, 30min before Aβ injection, prevented the increase in
NE concentrations. Our hypothesis that noradrenergic system
activation could be mediated by NO release after NOS induction
was supported by the observation that the increase in NE
concentrations was prevented in Aβ-treated rats with the
administration of different NOS inhibitors, 7-NI, and L-NIL.
Indeed, the administration of both compounds completely
prevented the increase in NE concentrations in all areas
investigated, indicating that activation of NOS is necessary for
this action to occur.
Furthermore, the altered release of NE may be explained
through the release of other neuromodulators, such as cytokines.
In this regard, Kamikawa and colleagues have reported that
increased NE levels occur in mPFC via indirect glutamate release.
In particular, the activation of IL-1β receptors at glutamatergic
terminals leads to the release of glutamate acting at non-NMDA
receptors in nerve terminals that induce NOS activation and then
NO production (Kamikawa et al., 1998). We have previously
demonstrated that an intra-hippocampal administration of Aβ
evoked an increased release of IL-1β through a purinergic
receptor (P2X7)-mediated mechanism (Sanz et al., 2009). Thus,
we hypothesized that Aβ-dependent release of IL-1β may
be able to generate such a cascade. Our hypothesis was
pharmacologically confirmed, considering that blocking the IL-1
receptors inhibited the Aβ-induced increase of NE. Furthermore,
a direct action of IL-1β on its receptors localized on glutamatergic
terminals in the mPFC seems to be responsible for an initial
release of NE after IL-1β injection (Kamikawa et al., 1998).
This observation appears very interesting for our research, since
we have recently demonstrated that, in a microdialysis study
conducted in this same experimental model, Aβ was able to elicit
an increase in the release of glutamate in PFC 2h after a single
i.c.v. injection (Tucci et al., 2014).
On the other hand, many reports have indicated that Aβ
directly interacts with the noradrenergic system and in particular,
that Aβ directly binds to adrenergic receptors (Igbavboa et al.,
2006; Wang et al., 2011). Wang et al. (2011) demonstrated,
in vitro that Aβ may cause desensitization and subsequently
internalization of β2 adrenergic receptors in prefrontal cortical
neurons (Wang et al., 2011).
This increase in noradrenergic tone could also reflect a
neuroprotective phenomenon. In this regard, it has been reported
that NA can regulate glial activation and a valid approach
for neurodegeneration could rely on pharmacological strategies
leading to increase NA (Braun et al., 2014). Furthermore, in vitro
studies have evidenced a protective effect of NA toward toxicity
Aβ-induced by increasing neurotrophic factor expression via
activation of β adrenergic receptor signaling cascade (Counts
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FIGURE 3 | Neuronal NOS, iNOS, and eNOS mRNA content in PFC, HIPP, and NAC of male Wistar rats 2h after injection of water (5 µL i.c.v.; SHAM) or
Aβ (4 µM, 5 µL i.c.v.; Aβ). Data are expressed as mean ± SEM (n = 6 per group; Student’s t-test, *P < 0.05).
and Mufson, 2010; Liu et al., 2015). Reduced NA concentrations
in LC projecting areas facilitates the inflammatory reaction of
microglial cells after Aβ exposure, thus impairing microglial
migration and phagocytosis, thereby decreasing Aβ clearance
(Heneka et al., 2010). Interestingly, it has been reported that NA
inhibits iNOS induction after inflammatory stimuli in astrocytes
(Feinstein et al., 1993) and microglia (Dello Russo et al., 2004).
On the other hand, in vitro studies indicate that Aβ can alter
neurotransmitter release by interacting with presynaptic proteins
(Russell et al., 2012). In particular, the peptide was reported
to be able to be internalized at presynaptic level where it can
disrupt the complex synaptophysin/vesicle associate membrane
protein 2 (VAMP2) leading to increased vesicle priming and
exocytosis (Russell et al., 2012). NO can also interfere with
neurotransmission considering that cGMP signaling and S-
nitrosylation of proteins can cause enhanced presynaptic binding
of syntaxin with VAMP and synaptosomal-associated protein-25
(SNAP 25) (Meffert et al., 1996). Therefore, we can hypothesize
that the increased NA levels found in our model can be the
result of a presynaptic interaction of Aβ and NO signaling
molecules. Accordingly, it has been shown that NO recruitment
may represent a compensatory mechanism to enhance synaptic
transmission and plasticity in a transgenic model of early AD
(Chakroborty et al., 2015).
Here we also found that Aβ was able to decrease eNOSmRNA
only in HIPP. Such result is in agreement with literature data
showing that Aβ reduces eNOS activity (Gentile et al., 2004).
However, in our experience only HIPP seems to be affected.
A possible explanation may rely on anatomical structure since
HIPP is a close region to injection area. Moreover, it has been
reported that eNOS deficient mice have higher Aβ levels in HIPP,
indicating a putative interconnection in this area considering
that NO supplementation reduced Aβ production (Austin et al.,
2010, 2013). In this light, several reports indicated that the effect
of Aβ may be region specific (Kar et al., 2004; Mura et al.,
2012).
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FIGURE 4 | NOx levels in PFC, HIPP, and NAC of male Wistar rats 2h
after injection of water (5 µL i.c.v.; SHAM) or Aβ (4 µM, 5 µL i.c.v.; Aβ).
Data are expressed as mean ± SEM (n = 6 per group; Student’s t-test,
*P < 0.05 for PFC and NAC and *P < 0.01 for HIPP).
Ultimately, in our experimental conditions, we might possibly
exclude a widespread toxic property of soluble Aβ on brain
neurotransmitters. Indeed, 5-HT concentrations were not altered
by Aβ administration in all investigated areas at this time-point,
while we have previously found that in PFC the peptide reduced
such neurotransmitter content 7 days after i.c.v. infusion,
indicating that 5-HT impairment needs a longer time to occur
(Colaianna et al., 2010). Furthermore, we have previously shown
that i.c.v. injection or retrodialysis of Aβ leads to a significant
reduction in DA concentrations in the PFC (Trabace et al.,
2007). Thus, the effects of Aβ seem to be neurotransmitter-
specific. Moreover, we have previously shown that the used
concentrations of Aβ are not associated, at least acutely, with
gross neurotoxicity as shown by Hoechst nuclear staining
(Trabace et al., 2007). However, we cannot exclude, after Aβ
treatment, the presence of more subtle signs of toxicity. In
FIGURE 5 | NE levels in PFC, HIPP, and NAC of male Wistar rats 2h
after injection of water (5 µL i.c.v.; SHAM) or Aβ (4 µM, 5 µL i.c.v.; Aβ).
Animals received 10min before an i.c.v. injection of vehicle (saline, veh, 5µl) or
interleukin-1 receptor antagonist (IL-1ra, 100 ng 5µl−1). Data are expressed
as percentage of control (n = 5–6 per group; Two-way ANOVA with Bonferroni
correction, *P < 0.05).
this regard, evaluation of sign of toxicity/apoptotic pathway
activation could represent an interesting future field of research.
In conclusion, we have demonstrated that the noradrenergic
system seems to be activated possibly as a compensatory
mechanism following soluble Aβ increased levels. In particular,
the modulation of nitrergic system and involvement of IL-1
receptors seem to play a crucial role in this process. Our results
contribute to shed light on the physiological interplay among
soluble Aβ, nitrergic and noradrenergic transmissions in the
brain.
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